G2B BioSolutions ApS: Financial statements 2025
CVR: 42437069
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
G2B BioSolutions ApS (CVR 42437069) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 44,817 and a net result of DKK 136,864 compared with DKK 370,740 the year before. That is a decrease of 89.7% compared with the year before. Equity in the 2025 report amounted to DKK -1,213,372.
- Gross Profit
- DKK 44,817
- Profit/Loss
- DKK 136,864
- Equity
- DKK -1,213,372
- Total Assets
- DKK 634,769
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 45 t. | 137 t. | -1.2 mio. | 0 |
| 2024 | - | 436 t. | 371 t. | -1.4 mio. | 1 |
| 2023 | - | -740 t. | -1.5 mio. | -1.7 mio. | 2 |
| 2022 | - | -171 t. | -219 t. | -207 t. | 1 |
Official annual report
How creditworthy is G2B BioSolutions ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
G2B BioSolutions ApS has published its annual report for 2024. Gross profit came to DKK 435,674, and the net result was DKK 370,740.
About G2B BioSolutions ApS
G2B BioSolutions ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Dayanand Suryabhan Jadhav. The company is owned by Dayanand Jadhav Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 44,817 and a net result of DKK 136,864 compared with DKK 370,740 the year before. Equity in the 2025 report amounted to DKK -1,213,372.